Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST266 in COVID-19
NCT04720378Phase 1Completed
- Sponsor
- Noveome Biotherapeutics
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ST266 in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) (4 cohorts), sponsored by Noveome Biotherapeutics. Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events at 3 months. Started May 2021; status: completed.
02
Drugs
ST266
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04720378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720378.